Tassos Gianakakos Net Worth: Estimate, Sources, Discrepancies

Based on publicly available evidence from SEC filings, employment agreements, and corporate disclosures, Tassos Gianakakos (full name: Anastasios E. Gianakakos) has an estimated net worth in the range of $20 million to $50 million as of May 2026. If you were specifically looking for Takis Georgakopoulos net worth, you should treat it as a separate figure and verify it directly from credible financial disclosures. That range is built primarily on his equity compensation and salary as founding CEO of MyoKardia, a cardiovascular biotech company acquired by Bristol Myers Squibb in 2020 for $13.1 billion, plus his board roles and prior senior positions at companies including Codexis, Merck, Maxygen, and MAP Pharmaceuticals.

Who Tassos Gianakakos is and why people search his net worth

Anastasios Gianakakos, known professionally as Tassos Gianakakos, is a Greek-American biotech executive whose name surfaces most prominently in connection with MyoKardia, a precision cardiovascular medicine company he helped lead as Chief Executive Officer. His employment as CEO was formally established by an agreement effective October 14, 2013, making him one of MyoKardia's founding leadership figures during its most formative years.

Interest in his net worth spiked after the Bristol Myers Squibb acquisition of MyoKardia closed in late 2020. Any founding or early-stage CEO who steers a biotech to a multi-billion-dollar acquisition is likely to have accumulated substantial equity, and that curiosity is completely reasonable. He also appears as a board member at LianBio, a biopharmaceutical company focused on Asia-Pacific markets, which adds another layer of visible professional activity that people connect to wealth.

One quick disambiguation note: if you searched for "Tassos Gianakakos" or "Tasso Gianakakos" or even "Anastasios Gianakakos," you are almost certainly looking at the same person. The name variations are just the formal versus informal Greek rendering of the same name. There is no widely known separate public figure in Greek business, sports, or entertainment who shares this name, so the biotech executive is the correct identification in this context.

The net worth estimate: what the range is and what drives it

The $20 million to $50 million range is a defensible estimate, not a confirmed figure. The lower bound accounts for a conservative reading of his equity stake at MyoKardia, offset by taxes and the possibility that much of his options vested across a long period rather than all at once at peak valuation. The upper bound reflects a more favorable reading: early-stage equity in a company acquired at $225 per share, combined with salary accruals, board compensation, and retained investments.

What really drives the number is the MyoKardia acquisition. Bristol Myers Squibb paid $13.1 billion in an all-cash deal. For a founding CEO who led the company from 2013 onward, equity accumulation over seven-plus years before exit is the single largest wealth driver. Even a fraction of a percent in equity or options at that valuation translates to tens of millions of dollars before tax. Beyond that, his accumulated base salary across leadership roles at multiple biotech and pharma companies over a roughly 25-year career adds meaningful earned income on top.

Where the estimate comes from: sources behind the numbers

Because Gianakakos is a U.S.-based executive at companies that were publicly traded or went through regulated acquisition processes, there are several legitimate data touchpoints, even if his personal wealth is never directly disclosed.

• SEC filings: MyoKardia filed documents with the U.S. Securities and Exchange Commission that reference Anastasios Gianakakos by name in his capacity as CEO. These filings often include proxy statements disclosing executive compensation, equity grants, and option schedules.
• Employment agreement (Justia): A publicly indexed employment agreement between MyoKardia and Anastasios Gianakakos as CEO, effective October 14, 2013, establishes the formal record of his founding leadership role and compensation structure.
• MarketScreener corporate profile: MarketScreener lists his full biography, prior roles, and board positions, giving a career map that allows for cross-referencing with known compensation structures at comparable companies.
• Bristol Myers Squibb acquisition documents: The $13.1 billion deal generated regulatory and financial disclosures that help analysts estimate what equity holders received at various ownership levels.
• LianBio board disclosures: His board role at LianBio, a company with its own funding rounds and public filings, provides additional compensation data points.

None of these sources directly states "Tassos Gianakakos's net worth is X." What they do is allow a reasonable reconstruction: take disclosed or estimated equity, apply the acquisition price, subtract estimated taxes, and add accumulated compensation from prior roles. That is the standard methodology for executive net worth estimates in the biotech sector, and it is the same approach used for comparable Greek-American business leaders in life sciences and technology.

Career earnings breakdown: where the money likely comes from

Gianakakos's career spans multiple decades across senior roles in biotech and pharma. Here is how the earnings layers stack up, working backward from the most significant event.

The MyoKardia chapter is clearly the defining wealth event. Before that acquisition, his career at Merck and Maxygen would have provided a solid professional foundation, but the step-change in wealth almost certainly came from founding-era equity crystallizing in the BMS deal.

Business and investment footprint in the Greek diaspora context

Gianakakos operates primarily within the U.S. biotech and life sciences ecosystem rather than within the Greek domestic market or the shipping and real-estate sectors more traditionally associated with Greek diaspora wealth. That places him in an interesting position relative to other high-profile Greek-American business figures whose fortunes are tied to property development or maritime trade.

His most visible current role beyond MyoKardia's legacy is his board position at LianBio, a company focused on bringing innovative medicines to greater China and other Asia-Pacific markets. That role signals active engagement in global biopharma rather than a retirement from professional life after the MyoKardia exit. It also represents a potential ongoing income stream through board compensation, which typically includes both cash retainers and equity grants at publicly listed or late-stage private companies.

There is no publicly confirmed evidence of major real estate holdings, shipping investments, or Greek domestic business stakes. That is consistent with a career built entirely within U.S. life sciences. By comparison, other prominent figures tracked in the Greek wealth space, such as those in property development or maritime enterprise, have more visible hard-asset footprints that make estimates easier to anchor. For Gianakakos, equity compensation and financial markets exposure are almost certainly the dominant asset classes.

Why net worth estimates for him vary so much online

If you have searched for this name and seen wildly different numbers on various websites, there are a few concrete reasons for that. These variations can include different assumptions about his overall net worth, including how much equity and compensation he ultimately realized.

1. Equity valuation timing: His MyoKardia equity was worth very different amounts depending on whether you measured it at founding (2013), at IPO, or at the BMS acquisition closing. Sites that pulled data at different points in that timeline will show dramatically different implied wealth.
2. Unknown exact ownership stake: SEC proxy statements disclose executive compensation but may not capture every equity grant in granular detail, especially for a company that spent several years private before listing. Private-phase grants are harder to trace.
3. Tax and vesting assumptions: Some estimates ignore capital gains taxes entirely, which can reduce gross equity proceeds by 20 to 37 percent in the U.S. context. Others assume all options were fully vested and exercised at peak price, which may be optimistic.
4. Name confusion and data recycling: Generic celebrity net worth aggregator sites often scrape and republish figures without verification. A number posted in 2020 at acquisition gets recycled in 2024 or 2025 without adjustment, even though personal wealth can shift significantly through reinvestment or additional compensation.
5. Private asset blindness: Any personal investments, real estate, or private company stakes are simply invisible to public data sources. This means all published estimates, including the range in this article, are necessarily incomplete.

How to verify or update this figure yourself

If you want to check whether this estimate has shifted, or if new information has emerged after May 2026, here is a practical checklist of what to look at and how often.

• SEC EDGAR (sec.gov): Search for 'Anastasios Gianakakos' or 'MyoKardia' to find historical proxy statements and compensation disclosures. This is the most reliable source for confirmed figures during his CEO tenure.
• LianBio filings: If LianBio remains publicly traded or files prospectus documents, look for board compensation tables that name him directly.
• MarketScreener and Bloomberg professional profiles: These aggregate corporate roles and can flag when he takes on new board seats or exits existing ones, which is a signal to check for new compensation disclosures.
• Crunchbase and PitchBook: Useful for tracking any new startup involvement or investment-stage companies where he may appear as an advisor or board member.
• Google News alerts: Set an alert for 'Anastasios Gianakakos' and 'Tassos Gianakakos' to catch any press releases, industry announcements, or credible media profiles that surface new financial details.
• Update frequency: Biotech executive wealth tied to a completed acquisition is relatively stable in the short term, but board equity and new ventures can shift things meaningfully. Checking every six to twelve months is reasonable unless a major corporate event (IPO, acquisition, funding round) triggers an earlier look.

Putting the estimate in perspective

A $20 million to $50 million estimated net worth places Gianakakos comfortably in the upper tier of Greek-American professional wealth, though well below the nine-figure and ten-figure territory occupied by figures in shipping, large-scale property development, or multi-generational family business empires. His wealth story is distinctly a life-sciences-era story: building equity in an innovative company over years, then crystallizing that value through a major acquisition. For more context on how people analyze figures like Panagiotis Tsakos net worth alongside biotech leadership outcomes, see the related breakdown for net worth drivers in comparable high-profile executives. That arc is increasingly common among Greek diaspora professionals who have built careers in U.S. technology and medicine rather than the traditional sectors.

The honest takeaway is this: his wealth is real, it is defensibly estimated, and the MyoKardia-to-BMS transaction is the clearest anchor for any calculation. But without direct personal disclosure, every number attached to his name, including the range here, carries genuine uncertainty. If you are specifically looking for Sakis Tanimanidis net worth, note that public disclosures may be limited and estimates can vary widely for different individuals every number attached to his name. Use it as a calibrated reference point, not a confirmed fact, and check the SEC and corporate filing sources listed above whenever you need the most current picture.